PTPN2 and neoplasm: Additionally, co-deletion of SOCS1 and PTPN2 in REGNASE-1-null T cells further enhanced anti-tumour immunity by improving mitochondrial function, indicating a promising therapeutic target for cancer immunotherapies [123, 147].